This trial is evaluating whether Icapamespib will improve 3 primary outcomes in patients with Relapse. Measurement will happen over the course of 7-14 days post surgery.
This trial requires 48 total participants across 2 different treatment groups
This trial involves 2 different treatments. Icapamespib is the primary treatment being studied. Participants will be divided into 2 treatment groups. There is no placebo group. The treatments being tested are in Phase 1 and are in the first stage of evaluation with people.
Relapse in an untreated brain tumour patient is associated with specific MR characteristics. Relapse is an ominous complication of the initial treatment of an untreated brain tumour, and the potential clinical impact of its timely detection is considerable.
Patients who are cured by the remission criteria experience a relapse rate of less than 5% per year. However, patients, as well as their spouses and social partners, feel that the patients' disability is increased significantly by the relapse during a 5-year period.
The most common cause of recurrent invasive [breast cancer](https://www.withpower.com/clinical-trials/breast-cancer) is local disease recurrence/regress. In breast cancer survivors, treatment failure is common; only 10% of the women with recurrent breast cancer were free of local disease for five years after initial breast treatment. The most common sites of recurrence are: axilla/breast/chest/skin recurrence (46%); local recurrence only (11%); recurrence in other organ sites (21%); and distant (sentinel site or metastasis) recurrence (7%).
Relapse rates following cannabis use (12-24 hours later following abstinence) were very high (42% to 89%, depending on method of relapse definition). Relapse rates after cannabis use are highest among persons with a history of relapse. Relapse is an important issue to consider before initiating cannabis use and after cannabis use for other reasons. Future efforts to minimize relapse following cannabis use warrant continuing efforts to implement relapse prevention counseling and strategies in clinical settings like publicly funded HIV clinics and substance abuse treatment programs.
Relapse prevention can be improved by incorporating relapse treatment in the management of HPV disease. We recommend addressing the psychosocial and social aspects related to emotional adjustment as well as smoking cessation, which might increase the patient's willingness for relapse treatment.
Relapse was strongly associated with family history of disease in univariate analysis but no difference was found when adjusting for familial history of disease in multivariate analysis. This may be possibly due to the nature of a family history in patients with sporadic disease.
ICAP was more effective than the placebo in terms of improvement of TTP and PFS and was significantly more active than placebo in terms of PFS and OS.
The relapse was mainly located in the lower limbs. The relapse was not found within one month (n=24; 14%) but was after 2 months (n=41; 26%; statistically significant). Although no statistically significant difference was detected, one patient (4.6%) continued to relapse throughout the 6 months of follow-up and another patient (5.4%) was still in partial remission at 6 months. After 9 months, the relapse was only in the lower limbs. Relapse was not found in the lower limbs after one or two months (n=46; 30%; statistically significant). After 9 months, the relapse was also in both limbs (n=42; 28%; non-significant).
This article presents the typical use of icapamespib in combination with other medications for the treatment of HR-positive/HER2-positive advanced/[metastatic breast cancer](https://www.withpower.com/clinical-trials/metastatic-breast-cancer), metastatic/localized advanced ovarian, or recurrent/persistent platinum-resistant uterine/serous ovarian cancer, and as a postprogression treatment of metastatic breast cancer. When combined with a taxane, icapamespib is a viable treatment option for women with advanced breast cancer.
The risk of relapse in our patients is not predicted by clinical features. Relapse of cancer and lymphoma after [treatment termination] may also be predicted by patient age, tumor site, histologic subtype, and presence of B or T cell lymphoproliferation, but this has not been adequately reported in the literature, and the conclusions that can be drawn need to be clarified.